The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.
 
Eisaku Miyauchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly; Merck; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Kyowa Kirin; Lilly
Research Funding - Boehringer Ingelheim; Chugai Pharma (Inst); Lilly (Inst)
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Eisai; Lilly Japan; MSD K.K.; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Nippon Boehringer Ingelheim (Inst)
 
Atsushi Nakamura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; CSL Behring; Kyowa Hakko Kirin; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kana Watanabe
No Relationships to Disclose
 
Satoshi Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Thermo Fisher Scientific
Research Funding - AstraZeneca; Chugai Pharma
 
Masahiro Seike
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Taiho Pharmaceutical
 
Yuka Fujita
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly
Research Funding - Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shin Nippon Biomedical (Inst)
 
Koichi Minato
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K
Research Funding - Bristol-Myers Squibb Japan (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Ryo Ko
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst)
 
Toshiyuki Harada
Honoraria - Boehringer Ingelheim; GlaxoSmithKline K.K.; Hisamitsu Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Boehringer Ingelheim
 
Koichi Hagiwara
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyorin; MSD Oncology; Novartis; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Taisho Toyama Pharma
Research Funding - Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - LSI Medience Corporation
 
Kunihiko Kobayashi
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan
 
Toshihiro Nukiwa
No Relationships to Disclose
 
Akira Inoue
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Mundipharma; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Shionogi
Consulting or Advisory Role - AstraZeneca; Lilly Japan; MSD
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Shionogi (Inst)